Bupropion induced hypertensive crisis in a healthy male with no prior hypertension

Authors

  • Nadia Siddiq Chaudhary Muhammad Akram Teaching and Research Hospital, Azra Naheed Medial College, Superior University Lahore Pakistan
  • Usama Abbas Chaudhary Muhammad Akram Teaching and Research Hospital, Azra Naheed Medial College, Superior University Lahore Pakistan
  • Noor Fatima Rauf Chaudhary Muhammad Akram Teaching and Research Hospital, Azra Naheed Medial College, Superior University Lahore Pakistan
  • Barak Waris Chaudhary Muhammad Akram Teaching and Research Hospital, Azra Naheed Medial College, Superior University Lahore Pakistan https://orcid.org/0009-0007-6405-2087
  • Nauman Ismat Butt Chaudhary Muhammad Akram Teaching and Research Hospital, Azra Naheed Medial College, Superior University Lahore Pakistan https://orcid.org/0000-0003-1022-0157

DOI:

https://doi.org/10.59736/IJP.23.03.969

Keywords:

Bupropion, Caffeine , Hypertension, Hypertensive Crisis, Norepinephrine Dopamine Reuptake Inhibitor

Abstract

Background: Bupropion is a norepinephrine-dopamine reuptake inhibitor (NDRI) indicated in treatment of depression, attention deficit hyperactivity disorder (ADHD) and for smoking cessation. Although hypertension is a known side effect, hypertensive crises in previously normotensive individuals is rarely reported.

Case Report: A 26-year-old male took bupropion for depressive symptoms during his exams, but his condition worsened after he started consuming excessive amounts of caffeine and energy drinks. The combination of bupropion and excessive caffeine intake led to hypertension and tachycardia. During his first visit to the emergency department, he presented with a blood pressure of 160/90 mmHg and a heart rate of 110 bpm. On a subsequent visit, these values had increased to 180/110 mmHg and 132 bpm, respectively. Workup ruled out other secondary causes. The symptoms resolved after discontinuation of bupropion.

Conclusion: Clinicians should monitor blood pressure in all patients, including those without known cardiovascular risk.

References

Clark A, Tate B, Urban B, Schroeder R, Gennuso S, Ahmadzadeh S, et al. Bupropion Mediated Effects on Depression, Attention Deficit Hyperactivity Disorder, and Smoking Cessation. Health Psychol Res. 2023; 11:81043. Doi: 10.52965/001c.81043.

Huecker MR, Smiley A, Saadabadi A. Bupropion. [Updated 2024 Sep 2]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK470212/.

Howes S, Hartmann-Boyce J, Livingstone-Banks J, Hong B, Lindson N. Antidepressants for smoking cessation. Cochrane Database Syst Rev. 2020; 4(4):CD000031. Doi: 10.1002/14651858.CD000031.pub5.

Han J, Kim M, Kim Y, Lee SH, Shin S, Choi YJ. Identifying Predictors of Serious Adverse Events in Antidepressant Treatment from a Decade-Long Nationwide Pharmacovigilance Study: Impact of Dementia and Parkinson's disease Treatment. Medicina (Kaunas). 2025; 61(6):1103. Doi: 10.3390/medicina61061103.

Harini K, Alomar SY, Vajagathali M, Manoharadas S, Thirumalai A, Girigoswami K, et al. Niosomal Bupropion: Exploring Therapeutic Frontiers through Behavioral Profiling. Pharmaceuticals (Basel). 2024; 17(3):366. Doi: 10.3390/ph17030366.

Waris B, Butt NI, Afzal A, Ghoauri MSA, Khizar I, Mahmood K, et al. Exploring knowledge of hypertension and treatment adherence in hypertensive patients from Lahore, Pakistan. Cureus. 2025; 17(4):e81762. Doi: 10.7759/cureus.81762.

Calvi A, Fischetti I, Verzicco I, Belvederi-Murri M, Zanetidou S, Volpi R, et al. Antidepressant Drugs Effects on Blood Pressure. Front Cardiovasc Med. 2021; 8:704281. Doi: 10.3389/fcvm.2021.704281.

Aronow WS. Drug-induced causes of secondary hypertension. Ann Transl Med. 2017; 5(17):349. Doi: 10.21037/atm.2017.06.16.

Kessler RC, Berglund P, Demler O, Jin R, Koretz D, Merikangas KR, et al; National Comorbidity Survey Replication. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA. 2003; 289(23):3095-105. Doi: 10.1001/jama.289.23.3095.

Kandukuru A, Sharma P, Verghese-Gupta S, Nkembo A, Sutariya V. Cardiovascular adverse events associated with norepinephrine-dopamine reuptake inhibitors: a pharmacovigilance study of the FDA Adverse Event Reporting System. Can J Physiol Pharmacol. 2024; 102(12):709-719. Doi: 10.1139/cjpp-2024-0128.

Ahmed H, Ismayl M, Palicherla A, Selim M, Aboeata A. Bupropion-disguised chest pain presenting in a middle-aged male: a case report and review of literature. Ann Med Surg (Lond). 2024; 86(7):4213-4216. Doi: 10.1097/MS9.0000000000002175

Downloads

Published

2025-09-29

Issue

Section

Case Reports

How to Cite

1.
Siddiq N, Abbas U, Rauf NF, Waris B, Butt NI. Bupropion induced hypertensive crisis in a healthy male with no prior hypertension. Int J Pathol [Internet]. 2025 Sep. 29 [cited 2025 Oct. 8];23(3):192-6. Available from: https://jpathology.com/index.php/OJS/article/view/969

Most read articles by the same author(s)